Jade Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
Jade Biosciences, Inc. (JBIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 100.49 thousand shares for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-04-25.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2025-04-25
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-03-31 was 100.49K shares, a 224.27% increase year-over-year.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2024-12-31 was 1.16M shares.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2024-09-30 was 1.90M shares.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2024-06-30 was 807.06K shares, a 3935.32% increase year-over-year.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 3.90M shares, a 4391.03% increase from fiscal 2023.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 86.89K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2025-03-31 | 100.49K shares 10-Q · filed 2025-04-25 | 1.26M shares derived: sum of 2 quarters · filed 2025-04-25 | 3.16M shares derived: sum of 3 quarters · filed 2025-04-25 | 3.97M shares derived: sum of 4 quarters · filed 2025-04-25 |
| 2024-12-31 | 1.16M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 3.06M shares derived: sum of 2 quarters · filed 2025-03-27 | 3.87M shares derived: sum of 3 quarters · filed 2025-03-27 | 3.90M shares 10-K · filed 2025-03-27 |
| 2024-09-30 | 1.90M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 2.71M shares derived: sum of 2 quarters · filed 2024-11-12 | 2.74M shares 10-Q · filed 2024-11-12 | 2.74M shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 807.06K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 838.05K shares 10-Q · filed 2024-08-12 | 838.05K shares derived: sum of 3 quarters · filed 2024-08-12 | 838.05K shares derived: sum of 4 quarters · filed 2024-08-12 |
| 2024-03-31 | 30.99K shares 10-Q · filed 2024-05-13 | 30.99K shares derived: sum of 2 quarters · filed 2024-05-13 | 30.99K shares derived: sum of 3 quarters · filed 2024-05-13 | 50.99K shares derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | 0.00 shares derived: sum of 2 quarters · filed 2024-03-25 | 20.00K shares derived: sum of 3 quarters · filed 2024-03-25 | 86.89K shares 10-K · filed 2024-03-25 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | 20.00K shares derived: sum of 2 quarters · filed 2023-11-13 | 86.89K shares 10-Q · filed 2023-11-13 | |
| 2023-06-30 | 20.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | 86.89K shares 10-Q · filed 2023-08-14 | ||
| 2023-03-31 | 66.89K shares 10-Q · filed 2023-05-15 | |||
| 2021-06-30 | 0.00 shares 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |